Goserelin
23 June, 2023
Hailey 24 Fe
23 June, 2023
Griseofulvin Tablets
Description
Generic name:
Griseofulvin
Drug class:
Systemic antifungal agent (oral)
Dosage form:
- Tablets: 125 mg, 250 mg
- Ultramicrosize and microsize formulations
Root of administration:
Oral
Dose:
- Adults: 500 mg to 1 g daily in divided doses
- Children: 10–25 mg/kg/day in divided doses
- Treatment duration: 4–8 weeks for skin infections; up to 6 months for nail infections
Mechanism of action:
Griseofulvin binds to fungal microtubules and inhibits mitosis, and deposits in keratin precursor cells to protect skin, hair, and nails from infection.
Drug usage cases:
- Approved: Tinea capitis
- Approved: Tinea corporis, cruris, pedis, barbae
- Off-label: Dermatophyte onychomycosis
- Off-label: Pityriasis rubra pilaris
Drug contra indications:
- Hypersensitivity to griseofulvin or formulation components
- Porphyria
- Severe hepatic impairment
- Pregnancy (Category X)
- Women of childbearing potential not using effective contraception
Side effects:
- Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain
- Central nervous system: Headache, dizziness, fatigue, confusion
- Dermatologic: Rash, urticaria, photosensitivity, exfoliative dermatitis
- Hematologic: Leukopenia, neutropenia, eosinophilia, thrombocytopenia
- Hepatic: Elevated liver enzymes, hepatotoxicity
- Endocrine: Gynecomastia
- Immunologic: Lupus-like syndrome, serum sickness–like reactions
Warnings:
- Hepatic impairment: Monitor liver function
- Hematologic effects: Monitor blood counts
- Porphyria: Contraindicated
- Photosensitivity: Advise sun protection
- CNS effects: Caution in seizure disorders
- Drug interactions: Induces CYP450; reduces efficacy of oral contraceptives, anticoagulants
- Superinfection: Monitor for bacterial or fungal overgrowth
Use during pregnancy or breastfeeding:
Griseofulvin is teratogenic and contraindicated in pregnancy (Category X). Women of childbearing potential must use effective contraception during therapy and for one month after. Griseofulvin is secreted in breast milk; breastfeeding is not recommended during treatment.
